April 21, 2026
PRMT5 Metabolomics Panel for Patient Stratification This poster presents a targeted, multiplexed LC-MS/MS metabolomics assay developed to support patient stratification and pharmacodynamic monitoring for MTA-cooperative PRMT5 inhibitors in oncology research. Leveraging Panome Bio’s specialized PRMT5 metabolomics panel, the assay enables sensitive and quantitative measurement of key metabolites associated with methylthioadenosine (MTA) biology and PRMT5 pathway […]
December 3, 2025
From Metabolism to Mechanism, Profile PRMT5 Activity in Cancer Profile PRMT5 activity with precise SDMA/ADMA quantification and full methionine cycle coverage. Support inhibitor development, patient stratification, and tumor profiling.
November 24, 2025
How Metabolomic Biomarkers Could Save PRMT5 Drug Development The PRMT5 inhibitor field represents one of the most expensive lessons in modern oncology drug development. Despite massive investments – including Bristol Myers Squibb’s $4.8 billion acquisition of Mirati Therapeutics and BeiGene’s $150 million MAT2A deal – the clinical results have been modest at best. With more […]
November 24, 2025
Two Targets, One Pathway: The Metabolomic Logic Behind MAT2A/PRMT5 Combination Therapies The next breakthrough in cancer treatment may come from attacking two targets within the same metabolic pathway. MAT2A and PRMT5 inhibitor combinations represent a new paradigm in precision oncology, using metabolic dependencies to create synthetic lethal interactions that spare normal cells while eliminating cancer […]
September 25, 2025
Why PRMT5 Clinical Trials Need Comprehensive Metabolomic Monitoring Current PRMT5 clinical trials are flying with incomplete instruments. While symmetric dimethylarginine (SDMA) has become the standard pharmacodynamic biomarker for monitoring PRMT5 inhibition, relying on this single metabolite provides only a narrow view of a complex biological network. Recent clinical setbacks and modest response rates suggest that […]
September 21, 2025
Measuring the Unmeasurable The most critical metabolites in PRMT5 research are also the most challenging to measure accurately. S-adenosylmethionine (SAM) and methylthioadenosine (MTA) are essential for understanding PRMT5 biology, but their inherent chemical instability has created an analytical bottleneck that’s limiting drug development progress. These highly reactive molecules spontaneously degrade during sample processing, creating artifacts […]
September 16, 2025
Why Genetic Biomarkers Aren’t Enough for PRMT5 Patient Selection The PRMT5 inhibitor field is facing a patient selection crisis that’s quietly undermining billion-dollar drug development programs. While genomic biomarkers promised to revolutionize precision oncology, mounting evidence suggests that MTAP (S-methyl-5′-thioadenosine phosphorylase) deletion status, the primary biomarker used to identify patients for PRMT5 inhibitor trials, may […]
September 8, 2025
Why Accurate SDMA and ADMA Measurement Is Essential for PRMT5 Inhibitors The protein arginine methyltransferase (PRMT) field has a measurement problem that’s quietly undermining drug development programs across the industry. While symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA) are both methylated arginine metabolites, their biological roles, and responses to PRMT inhibition, are fundamentally different. Yet […]
